Drugmaker Loses Jurisdiction Challenge Over Royalties Suit

By Silvia Martelli (May 3, 2022, 6:53 PM BST) -- The High Court ruled on Tuesday that a Japanese drugmaker can proceed with its lawsuit against British rival GW Pharma Ltd. as it does not directly concern the validity of foreign patents behind the seizure treatment for which GW Pharma allegedly owes outstanding royalties.

Ian Karet, sitting as a deputy High Court judge, said that the English courts have jurisdiction over Otsuka Pharmaceutical Co. Ltd.'s claim that GW Pharma has not paid royalties for a seizure treatment it created. This is because the case is not strictly concerned with the "validity and infringement" of jointly owned patents in Europe, Israel, Australia...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!